Rates, Risk Factors, and Outcomes of Nonvariceal Upper Gastrointestinal Bleeding in Patients Hospitalized for COVID-19 in the United States

Abstract

Objective

This study aimed to investigate the incidence and predictors of non-variceal upper gastrointestinal bleeding (NVUGIB) in hospitalized patients with coronavirus disease 2019 (COVID-19), as well as the inpatient outcomes associated with this complication.

Methods

This was an analysis of the National Inpatient Sample Database from January to December 2020. Adult COVID-19 patients were categorized into two groups based on NVUGIB development during hospitalization. Multivariate logistic analysis was performed to identify predictors and outcomes associated with NVUGIB in hospitalized COVID-19 patients in the US, after adjusting for age, sex, race, and Charlson Comorbidity Index (CCI) score, using Stata/BE 17.0.

Results

Among 1 050 045 hospitalized patients, 1.87% developed NVUGIB. Asian Americans had the highest risk, followed by Native Americans, Hispanics, and African Americans, with odds ratios (ORs) of 1.70, 1.59, 1.40, and 1.14, respectively. Patients with higher CCI scores were also at greater risk (with ORs of 1.47, 2.09, and 3.45 for CCI scores of 1, 2, and 3, respectively). COVID-19 patients with NVUGIB had a higher risk of inpatient mortality (OR=3.84), acute kidney injury (OR=3.12), hypovolemic shock (OR=13.7), blood transfusion (OR=7.02), and in-hospital cardiac arrest (OR=4.02).

Conclusion

NVUGIB occurred in 1.87% of hospitalized COVID-19 patients and was associated with a threefold increase in mortality. Further research is necessary to identify strategies for reducing its incidence in COVID-19 patients with multiple risk factors.

References

[1] Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol, 2020, 215: 108427

[2] Centers for Disease Control and Prevention. COVID Data Tracker, 2023 Atlanta, GA US Department of Health and Human Services, CDC May 16

[3] Gupta A, Madhavan MV, Sehgal K, et al.. Extrapulmonary manifestations of COVID-19. Nat Med, 2020, 26(7): 1017-1032

[4] Leung WK, To KF, Chan PKS, et al.. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology, 2003, 125(4): 1011-1017

[5] Guo YR, Cao QD, Hong ZS, et al.. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res, 2020, 7(1): 11

[6] Iqbal U, Anwar H, Siddiqui HU, et al.. Acute Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review and Meta-Analysis. Clin Endosc, 2021, 54(4): 534-541

[7] Negro A, Villa G, Rolandi S, et al.. Gastrointestinal Bleeding in COVID-19 Patients: A Rapid Review. Gastroenterol Nurs, 2022, 45(4): 267-275

[8] Musoke N, Lo KB, Albano J, et al.. Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res, 2020, 196: 227-230

[9] Kollias A, Kyriakoulis KG, Lagou S, et al.. Venous thromboembolism in COVID-19: A systematic review and meta-analysis. Vasc Med, 2021, 26(4): 415-425

[10] Iqbal U, Patel PD, Pluskota CA, et al.. Outcomes of Acute Gastrointestinal Bleeding in Patients With COVID-19: A Case-Control Study. Gastroenterology Res, 2022, 15(1): 13-18

[11] Trindade AJ, Izard S, Coppa K, et al.. Gastrointestinal bleeding in hospitalized COVID-19 patients: a propensity score matched cohort study. J Intern Med, 2021, 289(6): 887-894

[12] Makker J, Mantri N, Patel HK, et al.. The Incidence and Mortality Impact of Gastrointestinal Bleeding in Hospitalized COVID-19 Patients. Clin Exp Gastroenterol, 2021, 14: 405-411

[13] Zellmer S, Hanses F, Muzalyova A, et al.. Gastrointestinal bleeding and endoscopic findings in critically and non-critically ill patients with corona virus disease 2019 (COVID-19): Results from Lean European Open Survey on SARS-CoV-2 (LEOSS) and COKA registries. United European Gastroenterol J, 2021, 9(9): 1081-1090

[14] von Elm E, Altman DG, Egger M, et al.. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observation-al studies. Lancet, 2007, 370(9596): 1453-1457

[15] NIS Database Documentation. Accessed August 10, 2022. https://www.hcup-us.ahrq.gov/db/nation/nis/nis-dbdocumentation.jsp

[16] HCUP-US NIS Overview. Accessed January 2, 2023. https://www.hcup-us.ahrq.gov/nisoverview.jsp#about

[17] Yang J, Zheng Y, Gou X, et al.. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis, 2020, 94: 91-95

[18] Wan Y, Li J, Shen L, et al.. Enteric involvement in hospitalised patients with COVID-19 outside Wuhan. Lancet Gastroenterol Hepatol, 2020, 5(6): 534-535

[19] Al-Samkari H, Karp Leaf RS, Dzik WH, et al.. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 2020, 136(4): 489-500

[20] Xiao F, Tang M, Zheng X, et al.. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology, 2020, 158(6): 1831-1833.e3

[21] González González R, Jacob J, Miro O, et al.. Incidence, Clinical Characteristics, Risk Factors, and Outcomes of Upper Gastrointestinal Bleeding in Patients With COVID-19: Results of the UMC-19-S12. J Clin Gastroenterol, 2022, 56(1): e38-e46

[22] Li W, Xu Z, Xiang H, et al.. Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status. Aging (Albany NY), 2021, 13(7): 9225-9242

[23] Lawler PR, Goligher EC, Berger JS, et al.. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med, 2021, 385(9): 790-802

[24] Rostami M, Khoshnegah Z, Mansouritorghabeh H. Hemostatic System (Fibrinogen Level, D-Dimer, and FDP) in Severe and Non-Severe Patients With COVID-19: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost, 2021, 27: 10760296211010973

[25] Young PJ, Bagshaw SM, Forbes AB, et al.. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial. JAMA, 2020, 323(7): 616-626

[26] Plummer MP, Blaser AR, Deane AM. Stress ulceration: prevalence, pathology and association with adverse outcomes. Crit Care, 2014, 18(2): 213

[27] WHO REACT Working Group Sterne JAC, Murthy S, et al.. Association Between Admin-istration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA, 2020, 324(13): 1330-1341

[28] Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in Hospitalized Patients with COVID-19. N Engl J Med, 2021, 384(8): 693-704

[29] Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open, 2014, 4(5): e004587

[30] Pausawasdi N, Manomaiwong E, Kaosombatwattana U, et al.. The Effects of COVID-19 on Clinical Outcomes of Non-COVID-19 Patients Hospitalized for Upper Gastrointestinal Bleeding during the Pandemic. J Clin Med, 2022, 11(9): 2461

[31] Sethi A, Swaminath A, Latorre M, et al.. Donning a New Approach to the Practice of Gastroenterology: Perspectives From the COVID-19 Pandemic Epicenter. Clin Gastroenterol Hepatol, 2020, 18(8): 1673-1681

[32] Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet, 2000, 356(9238): 1318-1321

[33] Laursen SB, Gralnek IM, Stanley AJ. Raising the threshold for hospital admission and endoscopy in upper gastrointestinal bleeding during the COVID-19 pandemic. Endoscopy, 2020, 52(10): 930-931

[34] Ilagan-Ying YC, Almeida MN, Kahler-Quesada A, et al.. Increased Mortality in Patients Undergoing Inpatient Endoscopy During the Early COVID-19 Pandemic. Dig Dis Sci, 2022, 67(11): 5053-5062

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology